Download the ESMO 2012 Abstract Book - Oxford Journals

Annals of Oncology
89 Zr-trastuzumab for SPECT and PET respectively. A trial with 18 F-fluoroestradiol
in ovarian cancer is ongoing. Imaging of vascular endothelial growth factor
(VEGF) with 89 Zr-bevacizumab has been performed by us in various tumor types.
In addition, modulation of drug targets can be visualized by molecular imaging.
Down-regulation of HER2 and VEGF tumor expression by HSP90 inhibition and
of VEGF by mTOR inhibition was visualized in a human ovarian cancer bearing
mice. Finally, optical imaging can provide real-time visualization of small lesions
during surgery, allowing intra-operative staging and image-guided surgery. Folate
receptors are often over-expressed in ovarian cancer and in a pilot-study we
demonstrated, that ovarian cancer can be imaged intraoperatively by
folate-fluorescein-isothiocyanate (folate-FITC). We are currently performing a
feasibility fluorescence imaging study with the NIFR 800CW-bevacizumab tracer
in primary breast cancer. Molecular imaging is still in its infancy and not part of
current standards. However, the emerging possibilities of molecular imaging for
staging, treatment decision-making, monitoring of treatment effects and
image-guided surgery, justifies further validation of molecular imaging in ovarian
cancer.
Disclosure: E.G.E. De Vries: Research grant Roche and Novartis. All other authors
have declared no conflicts of interest.
Volume 23 | Supplement 9 | September 2012 doi:10.1093/annonc/mds380 | ix41